Poster

No Signs of MDMA-Related Histopathological Changes to CNS in Rats and Dogs in A 28-Day Repeated Oral Dose Neurotoxicity Study

3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy is being investigated as a potential treatment option for patients with posttraumatic stress disorder (PTSD). Previous animal MDM...

10/26/2023

Olanzapine/Samidorphan Effects on Weight Gain: A Pooled Analysis of Phase 2 and 3 Randomized, Double-Blind Studies

This pooled post hoc analysis compared the effects of a combination of olanzapine and samidorphan (OLZ/SAM) versus olanzapine on body weight after 12 weeks of treatment in patients with s...

10/26/2023

Medical Management of Capgras Syndrome with Underlying Lewy Body Dementia in an Elderly Patient with Mild Cognitive Impairment

A case report to evaluate and discuss the underlying pathology associated with both Lewy Body Dementia and Capgras syndrome, as well as the medical management and subsequent interventions...

10/26/2023

Medication Burden in Patients With Major Depressive Disorder Enrolled in Medicare Advantage Plans.

This study assessed real-world antidepressant treatment patterns and medication burden among Medicare Advantage Prescription beneficiaries with major depressive disorder (MDD). Adherence ...

10/26/2023

Long-term Safety, Tolerability, and Effectiveness of TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), in Patients With Schizophrenia (SHINE)

TV-46000 is a long-acting subcutaneous antipsychotic (LASCA). The SHINE study evaluated the long-term safety, tolerability, and effect of TV-46000 once monthly (q1m) and once every two mo...

10/26/2023

Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials

This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...

10/26/2023

Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder

This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...

10/26/2023

Maintenance Transcranial Magnetic Stimulation for Depression: A Meta-analysis

This meta-analysis aimed to assess the treatment effect of maintenance transcranial magnetic stimulation for depression. The analysis included 14 studies and 705 participants. Maintenance...

10/26/2023

Long-Term Efficacy of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...

10/26/2023

Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 study

In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...

10/26/2023